

- Dec 10, 2004
NCT00083551: UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur. UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy Sponsor University of Arkansas Collaborator Celgene Corpo
250


- Dec 9, 2004
NCT00081939: UARK 2003-33, Total Therapy III
UARK 2003-33, Total Therapy III Total Therapy 3 The UARK 2003-33, Total Therapy III - There have been two previous Total Therapy studies for multiple myeloma (MM) at the Myeloma Institute for Research and Therapy (MIRT): Total Therapy I (from 1989 through 1994) and Total Therapy II (from 1996 to 2004). Results have shown that patients treated on these studies had better outcomes (meaning patients have lived longer and had better responses to treatment) when compared to patien
249


- Dec 9, 2004
NCT00098475: Phase 3: Lenalidomide and Dexamethasone With or Without Thalidomide in Multiple Myeloma
ECOG-ACRIN Cancer Research Group ECOG E4A03 NCT00098475: Phase 3: Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma This randomized phase III trial studies lenalidomide and low-dose dexamethasone to see how well it works compared to lenalidomide and standard-dose dexamethasone, given with or without thalidomide, in treating patients with multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune s
223


- Dec 4, 2004
PMID 6546971: Effective treatment of advanced multiple myeloma refractory to alkylating agents
N Engl J Med May 24, 1984 Effective treatment of advanced multiple myeloma refractory to alkylating agents. Barlogie B, Smith L, Alexanian R. Twenty-nine patients with advanced refractory multiple myeloma were treated with intermittent high-dose dexamethasone in combination with four-day infusions of vincristine and doxorubicin. Rapid and marked tumor-mass reduction (greater than 75 per cent) was noted in 14 of 20 patients whose disease was resistant to alkylating agents and
259
- Dec 3, 2004
NCT00028886: Phase 3 - Combination Chemotherapy With or Without Thalidomide in Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor
319